Cargando…

Safety and Pharmacokinetic Assessment of Oral Proglumide in Those with Hepatic Impairment

Proglumide is an orally administered cholecystokinin receptor antagonist that was found to improve nonalcoholic steatohepatitis, reverse liver fibrosis, and decrease incidence of hepatocellular carcinoma (HCC) in animal models. The current investigation aimed to test the pharmacokinetics and safety...

Descripción completa

Detalles Bibliográficos
Autores principales:	Hsu, Christine C., Bansal, Sunil, Cao, Hong, Smith, Coleman I., He, Aiwu Ruth, Gay, Martha D., Li, Yaoxiang, Cheema, Amrita, Smith, Jill P.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2022
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8948956/ https://www.ncbi.nlm.nih.gov/pubmed/35336003 http://dx.doi.org/10.3390/pharmaceutics14030627

Ejemplares similares

Treatment with a Cholecystokinin Receptor Antagonist, Proglumide, Improves Efficacy of Immune Checkpoint Antibodies in Hepatocellular Carcinoma
por: Shivapurkar, Narayan, et al.
Publicado: (2023)

Proglumide Reverses Nonalcoholic Steatohepatitis by Interaction with the Farnesoid X Receptor and Altering the Microbiome
por: Gay, Martha D., et al.
Publicado: (2022)

Pharmacokinetic and metabolomic studies with a BIO 300 Oral Powder formulation in nonhuman primates
por: Li, Yaoxiang, et al.
Publicado: (2022)

Safety and Dosing Study of a Cholecystokinin Receptor Antagonist in Non‐alcoholic Steatohepatitis
por: Rabiee, Atoosa, et al.
Publicado: (2022)

4287 Extracellular vesicles as biomarkers for early detection of pancreatic cancer
por: Hinzman, Charles P, et al.
Publicado: (2020)

The Effects of Quinacrine, Proglumide, and Pentoxifylline on Seizure Activity, Cognitive Deficit, and Oxidative Stress in Rat Lithium-Pilocarpine Model of Status Epilepticus
por: Ahmad, Mohammad, et al.
Publicado: (2014)

68477 Pancreatic cancer cell extracellular vesicles drive the unfolded protein response in recipient normal pancreatic cells.
por: Hinzman, Charles, et al.
Publicado: (2021)

Cholecystokinin Receptor Antagonist Improves Efficacy of Chemotherapy in Murine Models of Pancreatic Cancer by Altering the Tumor Microenvironment
por: Malchiodi, Zoe X., et al.
Publicado: (2021)

Cholecystokinin Receptor Antagonist Induces Pancreatic Stellate Cell Plasticity Rendering the Tumor Microenvironment Less Oncogenic
por: Jolly, Gurbani, et al.
Publicado: (2023)

Urinary Metabolomics for the Prediction of Radiation-Induced Cardiac Dysfunction
por: Li, Yaoxiang, et al.
Publicado: (2023)

Pharmacokinetics, Safety, and Tolerability of Oral Semaglutide in Subjects With Hepatic Impairment
por: Bækdal, Tine A., et al.
Publicado: (2018)

Effects of Whole and Partial Heart Irradiation on Collagen, Mast Cells, and Toll-like Receptor 4 in the Mouse Heart
por: Sridharan, Vijayalakshmi, et al.
Publicado: (2023)

Novel H(2)S donor proglumide-ADT-OH protects HUVECs from ox-LDL-induced injury through NF-κB and JAK/SATA pathway
por: Ou, Xuelan, et al.
Publicado: (2021)

Effect of Hepatic Impairment on Eluxadoline Pharmacokinetics
por: Marbury, Thomas C., et al.
Publicado: (2017)

Pharmacokinetics of Nintedanib in Subjects With Hepatic Impairment
por: Marzin, Kristell, et al.
Publicado: (2017)

Effect of Hepatic Impairment on the Pharmacokinetics of Alectinib
por: Morcos, Peter N., et al.
Publicado: (2018)

The Effect of Hepatic Impairment on the Pharmacokinetics of Dacomitinib
por: Piscitelli, Joseph, et al.
Publicado: (2022)

Identification of Plasma Lipidome Changes Associated with Low Dose Space-Type Radiation Exposure in a Murine Model
por: Upadhyay, Maarisha, et al.
Publicado: (2020)

Safety and pharmacokinetics of cabazitaxel in patients with hepatic impairment: a phase I dose-escalation study
por: Sarantopoulos, John, et al.
Publicado: (2017)

The Effect of Hepatic Impairment on the Pharmacokinetics of Intravenously Administered Felcisetrag (TAK‐954)
por: Czerniak, Richard, et al.
Publicado: (2022)

Pharmacokinetics of ixazomib, an oral proteasome inhibitor, in solid tumour patients with moderate or severe hepatic impairment
por: Gupta, Neeraj, et al.
Publicado: (2016)

Effect of hepatic or renal impairment on the pharmacokinetics of evacetrapib
por: Small, David S., et al.
Publicado: (2016)

Pharmacokinetics and tolerability of semaglutide in people with hepatic impairment
por: Jensen, Lene, et al.
Publicado: (2018)

Pharmacokinetics of Cabotegravir in Subjects with Moderate Hepatic Impairment
por: Shaik, Jafar Sadik, et al.
Publicado: (2017)

Characterization of the Effect of Hepatic Impairment on Upadacitinib Pharmacokinetics
por: Trueman, Sheryl, et al.
Publicado: (2019)

Pharmacokinetics of Voxelotor in Patients With Renal and Hepatic Impairment
por: Preston, Richard A., et al.
Publicado: (2020)

The Pharmacokinetics and Safety of Tucatinib in Volunteers with Hepatic Impairment
por: Topletz-Erickson, Ariel R., et al.
Publicado: (2022)

Brigatinib pharmacokinetics in patients with chronic hepatic impairment
por: Hanley, Michael J., et al.
Publicado: (2023)

Pharmacokinetics of Gepotidacin in Subjects With Normal Hepatic Function and Hepatic Impairment
por: Hossain, Mohammad, et al.
Publicado: (2021)

TGFβ Drives Metabolic Perturbations during Epithelial Mesenchymal Transition in Pancreatic Cancer: TGFβ Induced EMT in PDAC
por: Rajagopal, Meena U., et al.
Publicado: (2021)

Plasma-derived extracellular vesicles yield predictive markers of cranial irradiation exposure in mice
por: Hinzman, Charles P., et al.
Publicado: (2019)

Evaluation of the Pharmacokinetics and Safety of a Single Dose of Acalabrutinib in Subjects With Hepatic Impairment
por: Xu, Yan, et al.
Publicado: (2022)

Evaluation of the Pharmacokinetics and Safety of a Single Oral Dose of Fasiglifam in Subjects with Mild or Moderate Hepatic Impairment
por: Marcinak, John, et al.
Publicado: (2018)

An Open-Label Study of the Impact of Hepatic Impairment on the Pharmacokinetics and Safety of Single Oral and Intravenous Doses of Omadacycline
por: Kovacs, Steven J., et al.
Publicado: (2020)

Influence of mild and moderate hepatic impairment on axitinib pharmacokinetics
por: Tortorici, Michael A., et al.
Publicado: (2010)

Pharmacokinetics of afatinib in subjects with mild or moderate hepatic impairment
por: Schnell, David, et al.
Publicado: (2014)

Insulin Degludec: Pharmacokinetic Properties in Subjects with Hepatic Impairment
por: Kupčová, Viera, et al.
Publicado: (2013)

Pharmacokinetics of conivaptan use in patients with severe hepatic impairment
por: Marbury, Thomas, et al.
Publicado: (2017)

Effect of hepatic impairment on pharmacokinetics, safety, and tolerability of lemborexant
por: Dayal, Satish, et al.
Publicado: (2021)

Effects of Hepatic Impairment on the Pharmacokinetics of Abrocitinib and Its Metabolites
por: Wang, Ellen Q., et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_3o9luc5vc5cv0vqhai9s2h7mlf